Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug

The Pharmacogenomics Journal volume 24, Article number: 13 (2024) Cite this article

Subjects

Abstract

To investigate the pharmacokinetic and pharmacodynamic profiles of volunteers carrying CYP2D6 genotypes with unknow metabolic phenotypes, a total of 22 volunteers were recruited based on the sequencing results. Peripheral blood and urine samples were collected at specific time points after oral administration of metoprolol. A validated high-performance liquid chromatography (HPLC) method was used to determine the concentrations of metoprolol and α-hydroxymetoprolol. Blood pressure and electrocardiogram were also monitored. The results showed that the main pharmacokinetic parameters of metoprolol in CYP2D6*1/*34 carriers are similar to those in CYP2D6*1/*1 carriers. However, in individuals carrying the CYP2D6*10/*87, CYP2D6*10/*95, and CYP2D6*97/*97 genotypes, the area under the curve (AUC) and half-life (t1/2) of metoprolol increased by 2-3 times compared to wild type. The urinary metabolic ratio of metoprolol in these genotypes is consistent with the trends observed in plasma samples. Therefore, CYP2D6*1/*34 can be considered as normal metabolizers, while CYP2D6*10/*87, CYP2D6*10/*95, and CYP2D6*97/*97 are intermediate metabolizers. Although the blood concentration of metoprolol has been found to correlate with CYP2D6 genotype, its blood pressure-lowering effect reaches maximum effectiveness at a reduction of 25 mmHg. Furthermore, P-Q interval prolongation and heart rate reduction are not positively correlated with metoprolol blood exposure. Based on the pharmacokinetic-pharmacodynamic model, this study clarified the properties of metoprolol in subjects with novel CYP2D6 genotypes and provided important fundamental data for the translational medicine of this substrate drug.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The pharmacokinetic profile of metoprolol in plasma and urine.
Fig. 2: Correlation of metoprolol blood concentration with systolic blood pressure.
Fig. 3: Correlation of metoprolol blood concentration with P-R prolongation.

Similar content being viewed by others

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38–54.

    Article  CAS  PubMed  Google Scholar 

  2. Gilani B, Cassagnol M. Biochemistry, Cytochrome P450. StatPearls: Treasure Island (FL), (2021).

  3. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A review of the important role of CYP2D6 in pharmacogenomics. Genes (Basel). 2020;11:1295.

    Article  CAS  PubMed  Google Scholar 

  4. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.

    Article  CAS  PubMed  Google Scholar 

  5. Jukic MM, Smith RL, Molden E, Ingelman-Sundberg M. Evaluation of the CYP2D6 haplotype activity scores based on metabolic ratios of 4,700 patients treated with three different CYP2D6 substrates. Clin Pharmacol Ther. 2021;110:750–8.

    Article  CAS  PubMed  Google Scholar 

  6. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, et al. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019;106:94–102.

    Article  PubMed  Google Scholar 

  7. Molden E, Jukic MM. CYP2D6 reduced function variants and genotype/phenotype translations of CYP2D6 intermediate metabolizers: implications for personalized drug dosing in psychiatry. Front Pharmacol. 2021;12:650750.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol. 2007;63:321–33.

    Article  CAS  PubMed  Google Scholar 

  9. Yang Q, Sun J, Li C, Zhang H, Xu W, Liu C, et al. Comparative research on the metabolism of metoprolol by four CYP2D6 allelic variants in vitro with LC-MS/MS. J Pharm Biomed Anal. 2019;174:479–85.

    Article  CAS  PubMed  Google Scholar 

  10. Regardh CG, Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet. 1980;5:557–69.

    Article  CAS  PubMed  Google Scholar 

  11. Borg KO, Carlsson E, Hoffmann KJ, Jonsson TE, Thorin H, Wallin B. Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol (Copenh). 1975;36:125–35.

    Article  CAS  PubMed  Google Scholar 

  12. Berger B, Bachmann F, Duthaler U, Krahenbuhl S, Haschke M. Cytochrome P450 enzymes involved in metoprolol metabolism and use of metoprolol as a CYP2D6 phenotyping probe drug. Front Pharmacol. 2018;9:774.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Qian JC, Xu XM, Hu GX, Dai DP, Xu RA, Hu LM, et al. Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics. 2013;14:1731–43.

    Article  CAS  PubMed  Google Scholar 

  14. Qian JC, Cai JP, Hu GX. Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties. Expert Opin Drug Metab Toxicol. 2021;17:707–16.

    Article  CAS  PubMed  Google Scholar 

  15. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30–4.

    Article  CAS  PubMed  Google Scholar 

  16. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110:888–96.

    Article  CAS  PubMed  Google Scholar 

  17. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102:213–8.

    Article  CAS  PubMed  Google Scholar 

  18. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018;103:770–7.

    Article  PubMed  Google Scholar 

  19. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37–44.

    Article  CAS  PubMed  Google Scholar 

  21. Neyshaburinezhad N, Ghasim H, Rouini M, Daali Y, Ardakani YH. Frequency of important CYP450 enzyme gene polymorphisms in the iranian population in comparison with other major populations: a comprehensive review of the human data. J Pers Med. 2021;11:804.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Vichi S, Buratti FM, Di Consiglio E, Turco L, Lautz LS, Darney K, et al. OpenCYP: An open source database exploring human variability in activities and frequencies of polymophisms for major cytochrome P-450 isoforms across world populations. Toxicol Lett. 2021;350:267–82.

    Article  CAS  PubMed  Google Scholar 

  23. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004;76:536–44.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81973397), the Natural Science Foundation of Zhejiang Province (LTGC23H310001), and the National Key Research and Development Program of China (2020YFC2008301).

Author information

Authors and Affiliations

  1. Institute of Molecular Toxicology and Pharmacology, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China

    Jianchang Qian, Tao Xu, Guoxin Hu & Jianping Cai

  2. Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China

    Peipei Pan

  3. Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

    Wei Sun

  4. The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100005, China

    Jianping Cai

Authors
  1. Jianchang Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peipei Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guoxin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jianping Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jianchang Qian and Tao Xu wrote the main manuscript text. Tao Xu, Peipei Pan and Wei Sun conducted the experiment, analysis the results, and prepared the figures/tables. Jianping Cai and Guoxin Hu designed the experiment. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Jianchang Qian, Guoxin Hu or Jianping Cai.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qian, J., Xu, T., Pan, P. et al. Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug. Pharmacogenomics J 24, 13 (2024). https://doi.org/10.1038/s41397-024-00332-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41397-024-00332-3

Search

Advanced search

Quick links